Hepatocellular carcinoma (HCC) is a challenging malignancyof global importance and is associated with a high rate ofmortality. Individuals with chronic viral hepatitis and otherforms of liver disease are at risk for developing HCC. Thestage of cancer dictates the therapeutic choice, making earlydetection a primary objective. Many observational studieshave reported that HCC is diagnosed at an earlier stage inpatients who received surveillance. The guidelines of theAmerican Association for the Study of Liver Diseases suggestthat surveillance should be performed using ultrasonographyat an interval of every 6–12 months. This interval is basedupon mainly observational data and the expected growthrates of HCC. Patients with abnormal screening tests requireadditional investigation using computed tomography scanning,magnetic resonance imaging, or liver biopsy. Althoughthe optimal methods of screening and the cost-effectivenessof surveillance for HCC remain to be established, systematicscreening still offers the best hope for early diagnosis,treatment eligibility, and improved survival.
|Numero di pagine||6|
|Stato di pubblicazione||Published - 2009|
All Science Journal Classification (ASJC) codes